
AARD Stock Forecast & Price Target
AARD Analyst Ratings
Bulls say
Aardvark Therapeutics is facing a temporary hold on its Phase 3 clinical trial for ARD-101 due to a QRS prolongation signal in healthy volunteers, but management has reiterated that this carries limited intrinsic arrhythmia risk and is reversible without medical intervention. The preliminary exposure-response modeling suggests lower doses fall below the threshold for QRS effect, giving the company flexibility in the next trial design. Management is confident in their ability to resolve the hold and has positive guidance from the FDA, although no specific timeline has been provided.
Bears say
Aardvark Therapeutics is facing significant risks, including the failure of lifting the clinical hold on ARD-101, negative clinical results from the Phase 3 HERO trial, and the potential partnership and geopolitical risks. Based on a discounted cash flow valuation, the company's total enterprise value is estimated to be $168M, with a corresponding 12-month price objective of $6 per share.
This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares